EMA Says Yes To GSK’s Omjjara, UCB’s Rystiggo and Novartis’ Spexotras

Three orphan drugs were among the eight products recommended for pan-EU marketing approval by the European Medicines Agency this week, while Novartis withdrew its filing for Vijoice.